SCHEMBL6457787

SCHEMBL6457787

COc1ccc(-c2cc(-c3ccc(OC)cc3)n(-c3ccccc3)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.60
LMNA P02545 2/20 0.60
HTT P42858 1/20 0.60
PTGS2 P35354 6/20 0.59
PTGS1 P23219 3/20 0.59
RPA1 P27694 2/20 0.59
FABP3 P05413 1/20 0.54
FABP4 P15090 1/20 0.54
EGFR P00533 1/20 0.53
NPY5R Q15761 1/20 0.53
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
HPGD P15428 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.51
POLB P06746 1/20 0.51
CYP2C9 P11712 1/20 0.51
KDM4E B2RXH2 2/20 0.50
CDK1 P06493 1/20 0.50
CDK4 P11802 1/20 0.50
CCNB1 P14635 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28873587 0.98 RPA1 (0.61) ALDH1A1LMNAHTTPTGS2PTGS1
SCHEMBL11391264 0.94 RPA1 (0.67) ALDH1A1LMNAHTTPTGS2PTGS1
SCHEMBL15452759 0.93 PTGS2 (0.69) ALDH1A1LMNAHTTPTGS2PTGS1
SCHEMBL5214995 0.92 PTGS2 (0.67) PTGS2PTGS1RPA1FABP3FABP4
SCHEMBL13029788 0.86 RAB9A (0.53) ALDH1A1PTGS1RPA1FABP3FABP4
SCHEMBL3852411 0.85 RAB9A (0.62) ALDH1A1LMNAHTTPTGS1RPA1
SCHEMBL8291470 0.85 PTGS2 (0.68) ALDH1A1LMNAPTGS2PTGS1RPA1
SCHEMBL29505126 0.85 ALDH1A1 (0.55) ALDH1A1LMNAHTTPTGS2PTGS1
SCHEMBL15714178 0.85 ALDH1A1 (0.60) ALDH1A1LMNAHTTPTGS2PTGS1
SCHEMBL13166592 0.85 ALDH1A1 (0.63) ALDH1A1LMNAHTTPTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050130971-A1 Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury PHARMACIA CORPORATION 2005-06-16 US disclosed
WO-2000019994-A1 ESTROGEN RECEPTOR LIGANDS BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2000-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130971-A1 Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury PDE2A, PDE3B, PDE3A ALDH1A1 845/4885LMNA 2444/4885HTT 3758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.